Voluntary announcement completion of enrollment of the first patient in the multi-center phase iib clinical trial of rifaquizinone (tnp-2092) administered via intra-articular injection for the treatment of prosthetic joint infection
Filed with HKEX · Stock code 6872 ·
6ix is reading this filing.
View original source (HKEXnews)TenNor Therapeutics Suzhou Ltd. on 6ix
Earlier from TenNor Therapeutics Suzhou
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Form of proxy for 2026 second extraordinary general meeting to be held on October 23, 2026
- Notice of 2026 second extraordinary general meeting
- Circular of 2026 second extraordinary general meeting
- 2026 Interim report
Later from TenNor Therapeutics Suzhou
- Poll results of the 2026 second extraordinary general meeting held on Friday, October 23, 2026 and amendments to the articles of association
- Articles of Association
Follow TenNor Therapeutics Suzhou into a list and get an email when it puts out news.
Follow TenNor Therapeutics Suzhou